Activation of the Wnt/β-catenin signaling pathway is a hallmark of a number of solid tumors. We analyzed the regulation of the Wnt/β-catenin pathway in Acute Lymphoblastic Leukemia (ALL) and its role in the pathogenesis of the disease. We 
INTRODUCTION
The evolutionarily conserved Wnt-signaling pathway has pivotal roles during the development of many organ systems. Central to this pathway is a multiprotein scaffold consisting of adenomatous polyposis coli (APC), glycogen synthase kinase (GSK)-3β, axin, and the transcriptional cofactor β-catenin. In the absence of Wnt ligands, β-catenin levels are kept low through constitutive phosphorylation by GSK-3β, which leads to the ubiquitination and degradation of β-catenin [1] [2] [3] Recent studies have demonstrated a role for Wnt signal transduction at several stages of lymphocyte development and in the self-renewal of hematopoietic stem cells 5, 6 . All of them indicate a crucial role for the Wnt-signaling pathway in the proliferation of thymocytes and also of pro-B cells, suggesting that Wnt proteins can function as growth factors for progenitor cells of both the B-and T-cell lineages 4, 7, 8 .
Abnormal Wnt signaling has become a hallmark of some types of solid tumors, most notably colon and hepatocellular carcinomas 9, 10 , and has been commonly associated with mutations in the amino-terminal region of β-catenin that make the molecule resistant to processing through the degradation pathway or in other proteins in this pathway, like the APC gene 11 . In addition, the functional loss of Wnt antagonists can contribute to activation of the Wnt pathway and result in carcinogenesis through deregulation of cell proliferation and differentiation. Recent studies have shown that impaired regulation of Wnt-antagonists such as sFRP, Wif-1, Hdpr-1 and Dkk-3 by promoter hypermethylation is present in several human malignancies [12] [13] [14] [15] [16] [17] .
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Given that Wnt signals are important for the survival and expansion of lymphocyte progenitors, it has been suggested that dysregulated Wnt signaling could be a mechanism underlying lymphoid leukemogenesis. Recent studies in acute or chronic lymphoid leukemias have provided initial information implicating a role for Wnt signaling in malignant hematopoiesis. B cells of patients with chronic lymphocytic leukemia (CLL) have been shown to express several Wnt genes highly in proportion to normal B cells 18 . In addition, in pre-B-acute lymphoblastic leukemia (ALL), several abnormal fusion proteins can be present. The presence of the E2A-PBX1 fusion protein has been shown to induce the expression of Wnt-16 19 .
We have recently shown that the methylation of cytosine nucleotides in ALL cells may be the most important way of inactivating cancer-related genes in this disease. In fact, this epigenetic event can help to inactivate tumor-suppressive apoptotic or growtharresting responses and has prognostic impact in B-and T-ALL [20] [21] [22] . The presence in individual tumors of multiple simultaneously methylated genes is an independent factor in poor prognosis in both childhood and adult ALL in terms of both disease-free survival (DFS) and overall survival (OS). Interestingly, the Dkk-3 gene which negatively modulates Wnt7A signaling is frequently silenced by methylation in ALL 15, 23 . It can thus be speculated that the functional loss of Wnt antagonists can contribute to activation of the Wnt pathway in ALL, and may play a role in the pathogenesis and prognosis of the disease; however, this hypothesis has never been previously explored.
In this study, we demonstrate that silencing of the Wnt antagonists by promoter methylation contributes to constitutive activation of the Wnt signaling pathway in ALL and that activation of the Wnt signaling pathway is implicated in the pathogenesis of the disease.
MATERIALS AND METHODS

Cell lines and patients
Six ALL-derived cell lines (TOM-1, NALM-20, MY, LOUCY, JURKAT and TANOUE) were purchased from the DSMZ (Deutche Sammlung von Microorganismen und Zellkulturen GmbH, Braunschweig, Germany). Cells were grown at 37ºC under 5% CO 2 in humidified air in RPMI medium (Gibco-BRL, Burlington, Ontario, Canada) supplemented with 20 fetal bovine serum (Biochrome), 1% penicillin/streptomycin and 1% HEPES (Gibco-BRL, Burlington, Ontario, Canada).
We studied 261 consecutive patients (154 male; 107 female) with de novo ALL who were enrolled in successive multicenter studies of the "Programa para el estudio y tratamiento de las hemopatias malignas" (PETHEMA) Spanish study group. All these patients were referred to the Reina Sofia Hospital of Cordoba, Spain, from January 1990
to December 2004. The median age at diagnosis in the study population as a whole was 14 years (range, 0.5-82 years). Of these patients, 129 were children (median age, 5 years; range, 0.5-14 years) and 132 presented adult ALL (median age, 29 years; range, 15-82 years). Informed consent was obtained from the patient or the patient's guardians. This study was approved by the ethics committee at the University of Navarra.
Diagnosis was established according to standard morphologic, cytochemical and immunophenotypic criteria. Patients were studied at the time of initial diagnosis; were risk-stratified according to the therapeutic protocol used, which was always based on recognized prognostic features (including cytogenetics), and were entered in ALL protocols of PETHEMA group. For statistical analyses, children were also grouped according to the National Cancer Institute (NCI) risk-classification criteria 24 . The specific PETHEMA ALL treatment protocols in which these patients entered included ALL-89 (between 1990-1993; n= 51) and ALL-93 (between 1993-2004; n= 210). The design and results of these studies have been previously reported [25] [26] [27] . PETHEMA ALL-89 consisted in a five-drug induction therapy, followed by four cycles of early post-remission treatment during four months, and maintenance therapy for two years.
Patients in remission at the end of the first year were randomized to receive one six- Table 1 .
Methylation-specific PCR (MSP)
Bone marrow samples were obtained from all the patients at the time of diagnosis.
High-molecular weight DNA was prepared from mononuclear diagnostic marrow cells using conventional methods, frozen at -80ºC, and retrospectively analyzed to assess the role of methylation profile. In every case, the diagnostic bone marrow sample contained blast cells in a ratio of at least 70%. Methylation status of the CpG islands in the sFRP1, sFRP2, sFRP4, sFRP5, Wif-1, Dkk-3 and Hdpr-1 gene promoters was determined by genomic DNA bisulfite treatment followed by MSP as reported by Herman et al 28 .
Primer sequences of each gene for the unmethylated and methylated reactions have been reported elsewhere [12] [13] [14] [15] [16] . "Hot start" PCR was performed for 30 cycles consisting of denaturation at 95ºC for 1 min, annealing at 60ºC for 1 min, and extension at 72ºC for 1 min, followed by a final 7-min extension for all primer sets. The products were separated by electrophoresis on 2% agarose gel. Bone marrow mononuclear cell and peripheral lymphocyte DNAs from healthy donors were used as negative control for methylation-specific assays. Human male genomic DNA universally methylated for all genes (Intergen Company, Purchase, NY) was used as a positive control for methylated alleles. Water blanks were included with each assay. 
Efficiencies (E) of each gene were calculated from the slopes of crossover points (Cp)
vs DNA concentration plot, according to the formula E = 10 (-1/slope) . ∆Cp corresponded to the difference between control/calibrator Cp and sample Cp, either for the target or for the reference sequences. The selected controls/calibrators were normal lymphocytes from healthy donors. They were considered as 100 % expression. fetal bovine serum and maintained at 37°C in a humid atmosphere containing 5% CO 2 .
Cell lines were treated with 2 and 4 µM of 5-Aza-2'-deoxycytidine (Sigma-Aldrich, Steinheim, Germany) for four days. After treatment, cells were washed in PBS, pelleted by centrifugation at 1500 rpm during 5 min and used for genomic DNA and RNA isolation. DNA was extracted using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) and total RNA using Rneasy  Mini Kit (Qiagen, Hilden, Germany). One microgram of total RNA was used for cDNA synthesis using SuperScript II RNase H-RT (Invitrogen Life Technologies, Paisley, UK) with random hexamers.
Protein extraction
Cell pellets were resuspended in lysis buffer containing 1% Triton X-100, 50 mM Tris HCl (pH 8), 150 mM NaCl, 1% Aprotinin-leupeptin, 1mM Na 3 VO 4, 10 mM NaF and ranging from one to seven methylated genes (Fig. 2C ). Other risk factors including cytogenetic groups were similarly distributed between the two groups defined by Wnt inhibitors promoter methylation (Table 1) . In a small group of patients (n=17), bone marrow samples were obtained at the time of diagnoses and after relapse for analysis of methylation of WNT inhibitors. Interestingly, the same genes were methylated at diagnoses and after relapse suggesting that the methylation pattern is not altered at the time of relapse in the majority of patient (not shown). Samples obtained from patients in CR showed no abnormal methylation of any of the WNT inhibitors.
Hypermethylation of Wnt inhibitors is associated with constitutive activation of the Wnt pathway in ALL
To demonstrate that the Wnt signaling pathway was activated in ALL, we analyzed the Fig. 3A and 3B ).
In addition, we demonstrated by western blot that β-catenin was mostly localized in the nuclear fraction (Fig. 3C) . The fact that treatment with 5-Aza-2'-deoxycytidine induced 3A and 3B) and that nuclear localization of β-catenin was reduced (Fig. 3C ) after demethylation indicates that hypermethylation of Wnt inhibitors is at least in part responsible for constitutive activation of the Wnt pathway in ALL. Consistent with this hypothesis, transcript levels of Wnt-16 (mean N: 190% vs 90%, P = 0.006, Fig. 4A ), Fz-3 (mean N: 300% vs 210%, P = 0.05, Fig. 4B ), Tcf-1 (mean N: 260% vs 50%, P = 0.01, Fig. 4C ), Lef-1 (mean N: 225% vs 25%, P = 0.0001, Fig. 4D ) and Cyclin D1 (mean N:
170% vs 32%, P = 0.003, Fig. 4E ) were significantly higher among methylated patients compared with non-methylated patients.
Inhibition of Wnt signaling leads to cell apoptosis in ALL
To determine whether constitutive activation of the Wnt signaling pathway is implicated in the pathogenesis of ALL, TOM-1 and NALM-20 cell lines were treated with Quercetin, an inhibitor of β-catenin/Tcf transcriptional activity 33 .
Incubation of ALL cells with Quercetin for 24 hours induced downregulation of Tcf-1, Lef-1 and cyclin D1
mRNA expression (Fig. 5A and B) and increased apoptosis as detected by an increase in oligonucleosomal fragments (Fig. 5C ) and confirmed by western blot analysis against PARP fragment (Fig. 5D ). Table 1 details the relapse history, CR rates and mortality for patients included in the different methylation groups. CR rates of patients in the methylated and non-methylated groups were 93% and 87%, respectively, accounting for an overall CR rate of 90%. This suggests that Wnt methylation profile did not correlate with response to remission induction therapy. However, patients in the non-methylated group had a lower relapse rate than patients in the methylated group (29% versus 59%, P = 0.0001). Mortality rate was also lower for non-methylated group compared with methylated group (36% versus 59%, P = 0.001). Similar results were obtained in a separate analyses of children (relapse rate, 19% for non-methylated group versus 47% for methylated group, P = 0.002; mortality rate, 16% for non-methylated group versus 30% for methylated group, P = 0.05) and adults (relapse rate, 43% for non-methylated group versus 72% for methylated group, P = 0.006; mortality rate, 62% for non-methylated group versus 83% for methylated group, P = 0.01).
Hypermethylation and silencing of Wnt inhibitors is associated with poor prognosis in ALL
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Estimated DFS at 10 years were 66% and 25% for non-methylated and methylated groups, respectively (P < 0.0001; Figure 6A ). Among children, the 10-year DFS was 77% for non-methylated group and 34% for methylated patients (P = 0.0003; Figure   6B ) while in adult ALL patients, the 10-year DFS was 48% for non-methylated group and 15% for methylated group (P = 0.005; Figure 6C ). The actuarial OS at 10 years calculated for all leukemic patients was 61% for non-methylated patients and 28% for methylated patients (P = 0.0003). Significant differences were observed in the actuarial OS among non-methylated and methylated groups in the separate analyses of children (82% and 49%, respectively, P = 0.05) and adults (34% and 10%, respectively, P = 0.01).
A multivariate analysis of potential prognostic factors demonstrated that hypermethylation profile was an independent prognostic factor in predicting DFS in the global series (P = 0.0001) as well as in both childhood (P = 0.001) and adult ALLs (P= 0.004; Table 2 ). Methylation status was also independently associated with OS in the global series (P = 0.01), adult ALL (P = 0.04) and childhood ALL (P = 0.01). Although a role for activation of the Wnt-signaling pathway in the pathogenesis of acute myeloid leukemia 34 , chronic lymphocytic leukemia 18 , chronic myeloid leukemia 35 We did not examine protein expression of Wnt inhibitors in part due to the fact that the goal of our study was to demonstrate that regulation expression of WNT inhibitors was at least in part due to epigenetic mechanisms in patients with ALL and also because the activation of the WNT pathway is demonstrated by the nuclear location of β-catenin and the reduced nuclear location after 5-Aza-2'-deoxycytidine treatment.
Recent studies have suggested that Wnt5a besides activating the canonical Wnt signaling may signal through the noncanonical Wnt/Ca ++ pathway to suppress cyclin D1 expression inhibiting B-cell proliferation and acting as a tumor suppressor gene 44 .
Furthermore, expression of Wnt5a was downregulated in the majority of patients with acute leukemia 44 . In our study, baseline expression of cyclin D1 in methylated patients was significantly higher than in normal lymphocytes ( Figure 4 ) and was only patients. Similarly, in the current study we divided the methylation groups into nonmethylated (no methylated genes) and methylated group (at least, one methylated gene)
as the statistical analyses of relapse rate, mortality rate, DFS and OS according to the
of methylated genes (from 0 to 7) showed that there was no statistically significant difference in prognosis between patients with 1-7 methylated but there was a large and significant difference in comparison with un-methylated patients. The presence in individual tumors of multiple epigenetic events that affect each of the pathways discussed above is a factor of poor prognosis in ALL. Our results not only provide further support for this hypothesis but also establish a potential mechanism by which hypermethylation contributes to the pathogenesis of ALL.
The current study has also potential clinical implications for patients with ALL. We clearly demonstrate that the methylation phenotype has a prognostic value both in terms of DFS and OS. Hence, the analysis of promoter methylation in patients with ALL could contribute to tailoring treatment strategies according to the prognosis. Most importantly, the demonstration that inhibition of β-catenin induces apoptosis of ALL establishes this pathway as an attractive target for the use of more specific therapies such as Quercetin 33 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 
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